COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; ENTRE 3 A 30% DE DANAZOL Y UNA FASE INTERNA Y FASE EXTERNA EN PROPORCION DE 50:50 A 85:15 EN PESO, EN EL QUE: LA FASE INTERNA NO LIPOIDEA CONTIENE POR LO MENOS UN POLIOL, TAL COMO GLICEROL, SORBITOL, ENTRE OTROS; Y LA FASE EXTERNA LIPOIDEA CON...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RILEY CUCA ROBERT C BORTZ JONATHAN THOMPSON DANIEL J |
| description | SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; ENTRE 3 A 30% DE DANAZOL Y UNA FASE INTERNA Y FASE EXTERNA EN PROPORCION DE 50:50 A 85:15 EN PESO, EN EL QUE: LA FASE INTERNA NO LIPOIDEA CONTIENE POR LO MENOS UN POLIOL, TAL COMO GLICEROL, SORBITOL, ENTRE OTROS; Y LA FASE EXTERNA LIPOIDEA CONTIENE AL MENOS UN ACEITE MINERAL O VEGETAL; UN EMULSIFICANTE, TAL COMO MONOISOESTEARATO DE GLICERILO, POLIGLICERIL-3-TRIOLEATO, ENTRE OTROS; Y UN AGENTE MODULADOR DE VISCOSIDAD, TAL COMO CERA MICROCRISTALINA Y/O SILICE HIDROFOBO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION TIENE LA FORMA FARMACEUTICA DE CREMA VAGINAL O SUPOSITORIO
A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PE20090249A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PE20090249A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PE20090249A13</originalsourceid><addsrcrecordid>eNrjZLB19vcN8A_2dPb091NwcwzydXR2DQ3xdHZUCHAMclRw9VEICXIMcfT1dPUL8VdwcVVw9XPx93UNCfIEagrmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxAa5GBgaWBkYmlo6GxsSoAQA9vSn1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS</title><source>esp@cenet</source><creator>RILEY ; CUCA ROBERT C ; BORTZ JONATHAN ; THOMPSON DANIEL J</creator><creatorcontrib>RILEY ; CUCA ROBERT C ; BORTZ JONATHAN ; THOMPSON DANIEL J</creatorcontrib><description>SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; ENTRE 3 A 30% DE DANAZOL Y UNA FASE INTERNA Y FASE EXTERNA EN PROPORCION DE 50:50 A 85:15 EN PESO, EN EL QUE: LA FASE INTERNA NO LIPOIDEA CONTIENE POR LO MENOS UN POLIOL, TAL COMO GLICEROL, SORBITOL, ENTRE OTROS; Y LA FASE EXTERNA LIPOIDEA CONTIENE AL MENOS UN ACEITE MINERAL O VEGETAL; UN EMULSIFICANTE, TAL COMO MONOISOESTEARATO DE GLICERILO, POLIGLICERIL-3-TRIOLEATO, ENTRE OTROS; Y UN AGENTE MODULADOR DE VISCOSIDAD, TAL COMO CERA MICROCRISTALINA Y/O SILICE HIDROFOBO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION TIENE LA FORMA FARMACEUTICA DE CREMA VAGINAL O SUPOSITORIO
A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090408&DB=EPODOC&CC=PE&NR=20090249A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090408&DB=EPODOC&CC=PE&NR=20090249A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RILEY</creatorcontrib><creatorcontrib>CUCA ROBERT C</creatorcontrib><creatorcontrib>BORTZ JONATHAN</creatorcontrib><creatorcontrib>THOMPSON DANIEL J</creatorcontrib><title>COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS</title><description>SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; ENTRE 3 A 30% DE DANAZOL Y UNA FASE INTERNA Y FASE EXTERNA EN PROPORCION DE 50:50 A 85:15 EN PESO, EN EL QUE: LA FASE INTERNA NO LIPOIDEA CONTIENE POR LO MENOS UN POLIOL, TAL COMO GLICEROL, SORBITOL, ENTRE OTROS; Y LA FASE EXTERNA LIPOIDEA CONTIENE AL MENOS UN ACEITE MINERAL O VEGETAL; UN EMULSIFICANTE, TAL COMO MONOISOESTEARATO DE GLICERILO, POLIGLICERIL-3-TRIOLEATO, ENTRE OTROS; Y UN AGENTE MODULADOR DE VISCOSIDAD, TAL COMO CERA MICROCRISTALINA Y/O SILICE HIDROFOBO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION TIENE LA FORMA FARMACEUTICA DE CREMA VAGINAL O SUPOSITORIO
A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB19vcN8A_2dPb091NwcwzydXR2DQ3xdHZUCHAMclRw9VEICXIMcfT1dPUL8VdwcVVw9XPx93UNCfIEagrmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxAa5GBgaWBkYmlo6GxsSoAQA9vSn1</recordid><startdate>20090408</startdate><enddate>20090408</enddate><creator>RILEY</creator><creator>CUCA ROBERT C</creator><creator>BORTZ JONATHAN</creator><creator>THOMPSON DANIEL J</creator><scope>EVB</scope></search><sort><creationdate>20090408</creationdate><title>COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS</title><author>RILEY ; CUCA ROBERT C ; BORTZ JONATHAN ; THOMPSON DANIEL J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PE20090249A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2009</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>RILEY</creatorcontrib><creatorcontrib>CUCA ROBERT C</creatorcontrib><creatorcontrib>BORTZ JONATHAN</creatorcontrib><creatorcontrib>THOMPSON DANIEL J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RILEY</au><au>CUCA ROBERT C</au><au>BORTZ JONATHAN</au><au>THOMPSON DANIEL J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS</title><date>2009-04-08</date><risdate>2009</risdate><abstract>SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; ENTRE 3 A 30% DE DANAZOL Y UNA FASE INTERNA Y FASE EXTERNA EN PROPORCION DE 50:50 A 85:15 EN PESO, EN EL QUE: LA FASE INTERNA NO LIPOIDEA CONTIENE POR LO MENOS UN POLIOL, TAL COMO GLICEROL, SORBITOL, ENTRE OTROS; Y LA FASE EXTERNA LIPOIDEA CONTIENE AL MENOS UN ACEITE MINERAL O VEGETAL; UN EMULSIFICANTE, TAL COMO MONOISOESTEARATO DE GLICERILO, POLIGLICERIL-3-TRIOLEATO, ENTRE OTROS; Y UN AGENTE MODULADOR DE VISCOSIDAD, TAL COMO CERA MICROCRISTALINA Y/O SILICE HIDROFOBO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION TIENE LA FORMA FARMACEUTICA DE CREMA VAGINAL O SUPOSITORIO
A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_PE20090249A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A29%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RILEY&rft.date=2009-04-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPE20090249A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |